{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T01:13:06Z","timestamp":1774746786803,"version":"3.50.1"},"reference-count":90,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T00:00:00Z","timestamp":1538265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Cardiovascular Disease"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p> In optimizing anticoagulation therapy, it is essential to balance treatment efficacy with the major adverse effect of anticoagulant treatment, bleeding risk. This narrative review examines the efficacy and safety of the non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban compared with standard anticoagulation or placebo. NOAC therapies provide equivalent to superior protection versus standard therapy, with similar or superior safety, and potential benefits in convenience. We will review the phase III evidence for each of the available NOACs in different antithrombotic indications, including atrial fibrillation (in the absence of significant mitral stenosis or mechanical heart valves); prophylaxis of venous thromboembolism (VTE) in patients undergoing orthopedic surgery; and acute and long-term treatment of VTE. Further, we will illustrate scenarios in which the evidence is stronger for a particular agent in the context of the overall positive safety and efficacy profile of NOACs in general. Limitations of the factor Xa inhibitors include the lack of a specific antidote in case of a bleeding emergency (an approved agent is available for reversing the effect of the direct thrombin inhibitor). We discuss the options for mitigating bleeding and describe the ongoing developments towards specific reversal agents. In conclusion, the available data for efficacy and safety, together with reliable pharmacokinetics obviating the need for regular monitoring, indicate that NOACs may offer substantial benefits for patients with nonvalvular atrial fibrillation or VTE. <\/jats:p>","DOI":"10.1177\/1753944718801554","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T06:14:52Z","timestamp":1538374492000},"page":"361-380","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence"],"prefix":"10.1177","volume":"12","author":[{"given":"Arthur","family":"Bracey","sequence":"first","affiliation":[{"name":"Baylor St. Luke\u2019s Medical Center, 6720 Berner Avenue, Rm P-125, Houston, TX 77030-3411, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wassim","family":"Shatila","sequence":"additional","affiliation":[{"name":"Texas Heart Institute, Houston, TX, USA"},{"name":"Baylor St. Luke\u2019s Medical Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Wilson","sequence":"additional","affiliation":[{"name":"Texas Heart Institute, Houston, TX, USA"},{"name":"Baylor St. Luke\u2019s Medical Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,9,30]]},"reference":[{"key":"bibr1-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2291"},{"key":"bibr2-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.708653"},{"key":"bibr3-1753944718801554","unstructured":"Bristol-Myers Squibb. Coumadin prescribing information, 2017, http:\/\/packageinserts.bms.com\/pi\/pi_coumadin.pdf (accessed 2 February 2018)."},{"key":"bibr4-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"bibr5-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"bibr6-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"bibr7-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"bibr8-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"bibr9-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"bibr10-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"bibr11-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113697"},{"key":"bibr12-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004450"},{"key":"bibr13-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306638"},{"key":"bibr14-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507"},{"key":"bibr15-1753944718801554","first-page":"302","volume":"19","author":"Casciano JP","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"bibr16-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6142"},{"key":"bibr17-1753944718801554","first-page":"615","volume":"10","author":"Roberts A.","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"bibr18-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1375"},{"key":"bibr19-1753944718801554","unstructured":"Bristol-Myers Squibb, Pfizer EEIG. Eliquis\u00ae (apixaban tablets) Summary of product characteristics, 2018, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf (accessed 14 April 2018)."},{"key":"bibr20-1753944718801554","unstructured":"Bristol-Myers Squibb Company PI. Eliquis (apixaban) prescribing information, 2018, http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf (accessed 14 April 2018)."},{"key":"bibr21-1753944718801554","unstructured":"Boehringer Ingelheim. Pradaxa (dabigatran) PI, 2018, https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf (accessed 7 April 2018)."},{"key":"bibr22-1753944718801554","unstructured":"Boehringer Ingelheim International GmbH. Pradaxa\u00ae (INN - dabigatran etexilate) summary of product characteristics, 2018, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf (accessed 28 April 2018)."},{"key":"bibr23-1753944718801554","unstructured":"Daiichi Sankyo C, Ltd. Savaysa\u00ae (edoxaban tablets). Prescribing information, 2017, http:\/\/dsi.com\/prescribing-information-portlet\/getPIContent?productName=Savaysa&inline=true (accessed 25 April 2018)."},{"key":"bibr24-1753944718801554","unstructured":"Daiichi Sankyo. Lixiana. Summary of product characteristics, 2018, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002629\/WC500189045.pdf (accessed 4 April 2018)."},{"key":"bibr25-1753944718801554","unstructured":"Janssen Pharmaceuticals. Xarelto (rivaroxaban) PI, 2017, http:\/\/dsi.com\/prescribing-information-portlet\/getPIContent?productName=Savaysa&inline=true (accessed 2 February 2018)."},{"key":"bibr26-1753944718801554","unstructured":"Bayer AG. Xarelto\u00ae (rivaroxaban) summary of product characteristics, 2018, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf (accessed 5 May 2018)."},{"key":"bibr27-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv309"},{"key":"bibr28-1753944718801554","unstructured":"Portola Pharmaceuticals. Bevyxxa\u00ae (betrixaban) prescribing information, 2018, https:\/\/www.bevyxxa.com\/wp-content\/uploads\/2017\/11\/bevyxxa-betrixaban-capsules-prescribing-information-pdf.pdf (accessed 14 April 2018)."},{"key":"bibr29-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207541"},{"key":"bibr30-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432"},{"key":"bibr31-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1407908"},{"key":"bibr32-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61445-7"},{"key":"bibr33-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02748.x"},{"key":"bibr34-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"bibr35-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-10-0679"},{"key":"bibr36-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.03.009"},{"key":"bibr37-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.09.011"},{"key":"bibr38-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2008.01.132"},{"key":"bibr39-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6"},{"key":"bibr40-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"bibr41-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810773"},{"key":"bibr42-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006885"},{"key":"bibr43-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62125-5"},{"key":"bibr44-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60734-0"},{"key":"bibr45-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1007378"},{"key":"bibr46-1753944718801554","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"Ruff CT","year":"2010","journal-title":"Am Heart J"},{"key":"bibr47-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"bibr48-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.004747"},{"key":"bibr49-1753944718801554","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-10-201111150-00004"},{"key":"bibr50-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.090464"},{"key":"bibr51-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005008"},{"key":"bibr52-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr342"},{"key":"bibr53-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005754"},{"key":"bibr54-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu046"},{"key":"bibr55-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60986-6"},{"key":"bibr56-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595496"},{"key":"bibr57-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.112.664144"},{"key":"bibr58-1753944718801554","first-page":"5","author":"Kato ET","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"bibr59-1753944718801554","unstructured":"Food and Drug Administration. FDA draft briefing document for the cardiovascular and renal drugs advisory committee (CRDAC): ENGAGE-AF TIMI 48, http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM420704.pdf (accessed 3 March 2018)."},{"key":"bibr60-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022361"},{"key":"bibr61-1753944718801554","first-page":"3320","volume":"116","author":"Fuji T","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"bibr62-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.03.021"},{"key":"bibr63-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-09-0601"},{"key":"bibr64-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12109"},{"key":"bibr65-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-03-0176"},{"key":"bibr66-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-11-21"},{"key":"bibr67-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1700518"},{"key":"bibr68-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601747"},{"key":"bibr69-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13227"},{"key":"bibr70-1753944718801554","unstructured":"Boehringer Ingelheim. Praxbind (idarucizumab) injection, for intravenous use. Prescribing information, 2018, http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Praxbind\/Praxbind.pdf (accessed 4 April 2018)."},{"key":"bibr71-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502000"},{"key":"bibr72-1753944718801554","unstructured":"Portola Pharmaceuticals. Andexxa [prescribing information], 2018, https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM606687.pdf (accessed 15 May 2018)."},{"key":"bibr73-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510991"},{"key":"bibr74-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607887"},{"key":"bibr75-1753944718801554","first-page":"1322","volume":"11","author":"Laulicht B","year":"2013","journal-title":"J Thromb Haemost"},{"key":"bibr76-1753944718801554","unstructured":"Perosphere I. Antidote for new oral anticoagulants - PER977, 2018, http:\/\/www.perospherepharma.com\/content\/research\/per977.htm (accessed 5 March 2018)."},{"key":"bibr77-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.07.008"},{"key":"bibr78-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021831"},{"key":"bibr79-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782060"},{"key":"bibr80-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.02.010"},{"key":"bibr81-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078696"},{"key":"bibr82-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-03-0179"},{"key":"bibr83-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"bibr84-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.12.019"},{"key":"bibr85-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-09-0668"},{"key":"bibr86-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.07.036"},{"key":"bibr87-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-013-0055-y"},{"key":"bibr88-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1065.1065"},{"key":"bibr89-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-11-0758"},{"key":"bibr90-1753944718801554","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13117"}],"container-title":["Therapeutic Advances in Cardiovascular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753944718801554","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753944718801554","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753944718801554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:06:22Z","timestamp":1740765982000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753944718801554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,30]]},"references-count":90,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1177\/1753944718801554"],"URL":"https:\/\/doi.org\/10.1177\/1753944718801554","relation":{},"ISSN":["1753-9447","1753-9455"],"issn-type":[{"value":"1753-9447","type":"print"},{"value":"1753-9455","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,30]]}}}